Paolo Vigneri
Overview
Explore the profile of Paolo Vigneri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
2800
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Piazza D, Martorana F, Curaba A, Sambataro D, Valerio M, Firenze A, et al.
Curr Oncol
. 2024 May;
31(5):2796-2804.
PMID: 38785493
Introduction: In recent years, generative Artificial Intelligence models, such as ChatGPT, have increasingly been utilized in healthcare. Despite acknowledging the high potential of AI models in terms of quick access...
12.
Broggi G, Massimino M, Failla M, Filetti V, Rapisarda V, Ledda C, et al.
Pathol Res Pract
. 2024 May;
259:155350.
PMID: 38781764
Fluoroedenite-induced pleural mesothelioma (FE-induced-PM) is a rare and small subset of PM that shares with its asbestos-induced counterpart the same aggressive biological behavior and poor prognosis, but that differs from...
13.
Martorana F, Sano M, Valerio M, Fogli S, Vigneri P, Danesi R, et al.
Ther Adv Drug Saf
. 2024 Apr;
15:20420986231224214.
PMID: 38665218
Abemaciclib (ABE) in combination with endocrine therapy represents the mainstay treatment for either endocrine-resistant metastatic or high-risk early-stage HR+/HER2- breast cancer patients. Hence, an adequate knowledge of this agent pharmacodynamic,...
14.
Marino A, Pavone G, Martorana F, Fisicaro V, Motta L, Spampinato S, et al.
Int J Mol Sci
. 2024 Mar;
25(6).
PMID: 38542195
Despite significant advances in the management of antiretroviral therapy (ART), leading to improved life expectancy for people living with HIV (PLWH), the incidence of non-AIDS-defining cancers, including breast cancer, has...
15.
Martorana F, Scandurra G, Valerio M, Cufari S, Vigneri P, Sano M, et al.
J Oncol Pharm Pract
. 2023 Nov;
30(1):173-181.
PMID: 38018146
Objective: Oral metronomic cyclophosphamide has been used as a single agent or in combination with other drugs for several solid tumors with interesting results in disease palliation and mild to...
16.
Martorana F, Di Grazia G, Rosano G, Vecchio G, Conti C, Nucera S, et al.
Medicina (Kaunas)
. 2023 Oct;
59(10).
PMID: 37893593
Triple-negative breast cancer (TNBC) represents about 15% of all breast cancers and is usually characterized by aggressive clinical behavior and a poor prognosis. Four TNBC subgroups have been previously defined...
17.
Massimino M, Stella S, Tirro E, Pennisi M, Stagno F, Vitale S, et al.
Onco Targets Ther
. 2023 Oct;
16:803-816.
PMID: 37807980
Purpose: Chronic Myeloid Leukemia (CML) is a clonal disorder of the hematopoietic stem cell caused by expression of the oncoprotein. High levels have been associated to proliferative advantage of leukemic...
18.
Cipolla C, Vieni S, DAgati E, Grassi N, Genova P, Graceffa G, et al.
Anticancer Res
. 2023 Sep;
43(10):4643-4649.
PMID: 37772556
Background/aim: Clinical trials have shown that the sentinel lymph node biopsy (SLNB) is feasible for patients with cN1 breast carcinoma treated with neoadjuvant chemotherapy (NAC). This study aimed to evaluate...
19.
Massimino M, Martorana F, Stella S, Vitale S, Tomarchio C, Manzella L, et al.
Genes (Basel)
. 2023 Jul;
14(7).
PMID: 37510235
Cancer molecular profiling obtained with conventional bulk sequencing describes average alterations obtained from the entire cellular population analyzed. In the era of precision medicine, this approach is unable to track...
20.
Gebbia V, Martorana F, Scandurra G, Valerio M, Cufari S, Vigneri P, et al.
J Oncol Pharm Pract
. 2023 Jul;
30(5):853-859.
PMID: 37501558
Introduction: Metronomic oral cyclophosphamide (MOC) presents many potential advantages, such as significantly less severe side effects than standard regimens, ease of administration, and the delivery of a dose-dense but not...